Enfusion Q4 2023 Earnings Report

Enfusion EPS Results

• Actual EPS: $0.01
• Consensus EPS: $0.03
• Beat/Miss: Missed by -$0.02
• One Year Ago EPS: N/A

Enfusion Revenue Results

• Actual Revenue: $46.49 million
• Expected Revenue: $45.56 million
• Beat/Miss: Beat by +$930.00 thousand
• YoY Revenue Growth: N/A

Enfusion Announcement Details

• Quarter: Q4 2023
• Date: 3/12/2024
• Time: N/A

Enfusion (NYSE:ENFN) provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers Accounting/General Ledger System, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion Analytics System, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion, Inc. was founded in 1997 and is headquartered in Chicago, Illinois.